RT Journal Article
T1 Relationship between the Risk of Gastric Cancer and Adherence to the Mediterranean Diet According to Different Estimators. MCC—Spain Study
A1 Álvarez Álvarez, Laura
A1 Alguacil Ojeda, Juan
A1 Martín, Vicente
AB The aim was to assess the effect of adherence to the Mediterranean Diet, measured with five different indexes, on the risk of gastric cancer. Data come from the multicase-control study MCC—Spain, which included 354 gastric cancer cases and 3040 controls with data on diet. We used five indexes to evaluate adherence to the Mediterranean diet and assess the association between each pattern with the risk of gastric cancer, using multivariate logistic regression. The analyses were performed for the whole set of gastric cancer cases, by anatomical location (cardia and non-cardia) and by histological type (intestinal and diffuse). According to the used index, a high adherence protects one from gastric cancer (between 48% (aOR = 0.52; CI 95% = 0.28–0.94) and 75% (aOR = 0.25; CI 95% = 0.12–0.52)), from non-cardia (between 48% (aOR = 0.52; CI 95% = 0.36–0.75) and 65% (aOR = 0.35; CI 95% = 0.23–0.52)), and from the intestinal type (between 41% (aOR = 0.59; CI 95% = 0.36–0.95) and 72% (aOR = 0.28; CI 95% = 0.16–0.50)), but not from the diffuse type. In conclusion, high adherence to a Mediterranean diet pattern is a protective factor for the risk of gastric cancer, with greater adherence leading to greater protection
PB MDPI
SN 2072-6694 (electrónico)
YR 2021
FD 2021
LK http://hdl.handle.net/10272/20845
UL http://hdl.handle.net/10272/20845
LA eng
NO Álvarez-Álvarez, L.; Vitelli-Storelli, F.; Rubín-García, M.; Aragonés, N.; Ardanaz, E.; Castaño-Vinyals, G.; Obón-Santacana, M.; Dierssen-Sotos, T.; Salas-Trejo, D.; Tardón, A.; et al. Relationship between the Risk of Gastric Cancer and Adherence to the Mediterranean Diet According to Different Estimators. MCC—Spain Study. Cancers 2021, 13, 5281. https:// doi.org/10.3390/cancers13215281
NO The study was partially funded by the “Accion Transversal del Cancer”, approved on theSpanish Ministry Council on 11 October 2007; by the Instituto de Salud Carlos III-FEDER (PI08/1770,PI08/0533, PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada, PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213,PI12/00488, PI12/00265, PI12/01270, PI12/00715, PI12/00150, PI14/01219, PI14/0613, PI15/00069,PI15/00914, PI15/01032, PI17CIII/00034); by the Fundación Marqués de Valdecilla (API 10/09); bythe ICGC International Cancer Genome Consortium CLL (the ICGC CLL-Genome Project is funded bySpanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud CarlosIII (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036));by the Junta de Castilla y León (LE22A10-2); by the Consejería de Salud of the Junta de Andalucía(PI-0571-2009, PI-0306-2011, salud201200057018tra); by the Conselleria de Sanitat of the GeneralitatValenciana (AP_061/10); by the Recercaixa (2010ACUP 00310); by the Regional Government of theBasque Country; by the Consejería de Sanidad de la Región de Murcia; by the European Commissiongrants FOOD-CT-2006-036224-HIWATE; by the Spanish Association Against Cancer (AECC) ScientificFoundation—grant GCTRA18022MORE; by the Catalan Government—Agency for Management ofUniversity and Research Grants (AGAUR) grants 2017SGR723 and 2014SGR850; by the FundaciónCaja de Ahorros de Asturias; and by the University of Oviedo. ISGlobal is a member of the CERCAProgramme, Generalitat de Catalunya. M Obón-Santacana received a post-doctoral fellowship fromthe Spanish Association Against Cancer (AECC) Scientific Foundation. M Obón-Santacana is part ofgroup 55 of CIBERESP and AGAUR 2017SGR723. M. R-G. is supported by the Ministry of Educationof Spain (FPU17/06488).
DS Repositorio Institucional de la Universidad de Huelva
RD 2 jun 2026